StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research note released on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Price Performance
Shares of NASDAQ TENX traded down $0.12 during midday trading on Thursday, hitting $3.08. 17,899 shares of the company’s stock traded hands, compared to its average volume of 162,274. The firm has a fifty day moving average of $3.31 and a 200 day moving average of $4.61. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Equities research analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Tenax Therapeutics
- How to Calculate Options Profits
- Should You Invest in Bitcoin? Pros and Cons
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.